Plain-English translation of NCT05123807 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a two-part treatment approach for women whose mucinous ovarian cancer has returned after their first round of treatment. The approach combines surgery to remove as much cancer as possible with hyperthermic intraperitoneal chemotherapy (HIPEC)—a procedure where heated chemotherapy is delivered directly into the abdomen during surgery. Researchers want to see how long women survive without their cancer getting worse and whether this combination approach is safe.
Mucinous ovarian cancer that comes back is very difficult to treat, and doctors need better options to help patients live longer and with a better quality of life. This trial is exploring whether combining surgery with heated chemotherapy delivered directly to the cancer site might work better than standard treatments alone.
You likely qualify if…
You likely don't qualify if…
You would have surgery to remove as much of the cancer as possible from your abdomen and pelvis. During that surgery, your surgeon would also perform HIPEC—warming chemotherapy and delivering it directly into your abdominal cavity for about 90 minutes before closing you up. After surgery, you would have follow-up visits to monitor your recovery, check how well you're doing, and see if your cancer comes back. The study will also collect blood and tumor samples to help researchers learn more about your cancer.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States